We have recently identi®ed the TSLC1 gene as a novel tumor suppressor in human non-small cell lung cancers. TSLC1 encodes a membrane glycoprotein with an extracellular domain homologous to those of immunoglobulin superfamily proteins. Truncation of TSLC1 in the cytoplasmic domain in a primary human tumor suggests that this domain is important for tumor suppressor activity. Here, we report the isolation of two TSLC1-like genes, TSLL1 and TSLL2, based on their structural homology with the sequences corresponding to the cytoplasmic domain of TSLC1. Signi®cant similarity was also observed in the extracellular domain as well as in the overall gene structure, indicating that these three genes form a unique subfamily (the TSLC1-gene family) in the immunoglobulin superfamily genes. In contrast to the ubiquitous expression of TSLC1, TSLL1 is expressed exclusively in adult and fetal human brain, while TSLL2 is expressed in several speci®c tissues including prostate, brain, kidney and some other organs. Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers. Oncogene (2001) 20, 5401 ± 5407.
Introduction
TSLC1 is a novel tumor suppressor gene on chromosome 11q23.2 involved in human non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and pancreas cancer (Kuramochi et al., 2001) . We have demonstrated that restoration of TSLC1 expression to normal levels strongly suppressed tumor formation in nude mice by A549, a human NSCLC cell line. TSLC1 encodes a membrane glycoprotein containing three immunoglobulin-like C2-type domains, one transmembrane domain, and a short cytoplasmic domain. Signi®cant homology of the extracellular domain with those of immunoglobulin superfamily proteins, including NCAM1 or NCAM2, suggests that TSLC1 could be involved in cell adhesion. On the other hand, the cytoplasmic domain of 46 amino acids showed signi®cant homology with that of glycophorin C, a protein required for anchoring protein 4.1 in the red blood cell (Marfatia et al., 1995) . Protein 4.1 is a member of family proteins containing ezrin, radixin, moesin, or merlin, which are involved in membrane-cytoskeleton interactions (Martin et al., 1995) . Furthermore, the COOHterminal portion of TSLC1 contains amino acid sequences that could possibly bind to the PDZ domains of other proteins. We found a frameshift mutation in the TSLC1 gene causing a protein truncation in the cytoplasmic domain in a primary human NSCLC (Kuramochi et al., 2001) , which suggests that the cytoplasmic domain could be critical for tumor suppressor activity of TSLC1.
In the present study, we cloned two human genes, TSLC1-like genes 1 and 2 (TSLL1 and TSLL2), which encode cytoplasmic domains homologous to those of TSLC1. Signi®cant homology in the overall coding sequences as well as in the exon-intron structure suggests that TSLC1, TSLL1, and TSLL2 form a unique subfamily (the TSLC1-gene family) in the immunoglobulin superfamily genes. Tissue-speci®c expression of these genes and loss of expression in several human cancer cell lines suggest that these two proteins could play some roles in relevant tissues as well as in their malignant progression to cancers.
Results

cDNA cloning of family genes of TSLC1
The amino acid sequence of the cytoplasmic domain of TSLC1, which shows signi®cant similarity with that of glycophorin C, was used for searching the homologous sequences in the database by BLAST program. Comparative analysis of amino acid sequences with corresponding nucleotide sequences identi®ed two distinct sequences of human genes, bk134P22.1 of 1296 bp (GenBank Accession No. CAB56227) and F22162_1 of 1143 bp (AAC32740), as homologous sequences. The bk134P22.1 was a predicted gene based on the genomic sequence of a BAC clone 134P22 of 118 951 bp (GenBank Accession No. AL035403), while the F22162_1 was predicted by the sequence of a cosmid clone F22162 of 35 465 bp (AC005525).
Because a fragment of bk134P22.1 was expressed in human adult brain tissues, a human brain-derived cDNA library was screened using the RT ± PCR product of the sequence as a probe, and seven independent cDNA clones were obtained. Full-length TSLL1 cDNAs of two distinct molecules of 2416 and 3557 bp caused by alternative polyadenylation sites were subsequently obtained ( Figure 1a ). Although bk134P22.1 was predicted to contain an open reading frame (ORF) of 1296 bp, both isoforms of TSLL1 cDNA we cloned contained a shorter ORF of 1194 bp encoding a protein of 398 amino acids, in which the sequence corresponding to the predicted exon 2 of the bk134P22.1 was not present. We designated this gene as TSLC1-like gene 1 (TSLL1).
F22162_1 did not contain a whole coding sequence. As this sequence was also expressed in human adult brain, we screened the human adult brain-derived cDNA library to obtain a full-length cDNA. The whole coding sequence and 5' untranslated region (UTR) of the gene were eventually determined by the RACE method and named TSLC1-like gene 2 (TSLL2) (Figure 1b ). TSLL2 cDNA of 2176 bp contains a single ORF of 1164 bp encoding a protein of 388 amino acids. The complete cDNA sequences of human TSLL1 and TSLL2 will be available from GenBank under Accession Nos. AF363367 and AF363368 respectively. a TSLL1 and TSLL2, family genes of the tumor suppressor TSLC1 H Fukuhara et al
Predicted amino acid sequences indicate that both TSLL1 and TSLL2 encode membrane proteins with an extracellular domain containing three immunoglobulinlike C2-type loops with several potential N-glycosylation sites, one transmembrane domain, and a short cytoplasmic domain. As shown in Figure 2 , TSLL1 displayed higher homology to TSLC1 than TSLL2 in the cytoplasmic domain (76 and 37% identical in the amino acid sequences, respectively). Moreover, TSLL1 and TSLL2 showed signi®cant similarity with TSLC1 in the whole amino acid sequences (37 and 37% identical in the amino acid sequences, respectively), indicating that both proteins belong to the immunoglubulin superfamily proteins.
Structure of the TSLL1 and TSLL2 gene
The genomic structure of the TSLL1 and TSLL2 was determined by the alignment of each cDNA sequence to the known genomic sequences of a BAC clone 134P22 (GenBank Accession No. AL035403) and a cosmid clone F22162 (AC005525), respectively. Portions of the genomic sequences of TSLL1 and TSLL2 were determined using BAC DNA from clones 431A20 and 343M13 as templates, respectively. The TSLL1 gene consists of nine exons spanning a region of about 30 kb, and exon 1 is followed by seven relatively small exons, ranging from 91 to 171 bp in size, and a large last exon 9 (Figure 3 ). Exon 1 contains the start codon of methionine, which is preceded by Kozak's consensus sequences (Kozak, 1989) .
The TSLL2 gene also consists of nine exons located within a region of 17 kb. The sequence closely related to that of Kozak was present in exon 1, followed by the start codon of methionine ( Figure 3) . The exon ± intron structures are highly conserved among TSLC1, TSLL1, and TSLL2 genes except for exon 8 of the TSLC1, and corresponding exons in each gene are almost the same in size. The upstream regions of the TSLL1 and TSLL2 genes are highly rich in the content of guanine and cytosine residues and meet the criteria of a CpG island of 754 and 1039 bp, respectively (Antequera and Bird, 1993) .
Chromosomal localization
To determine the chromosomal location of the TSLL1 and TSLL2 genes directly,¯uorescence in situ hybridization (FISH) was carried out. Human BAC clones 431A20 containing the TSLL1 gene and 343M13 containing the TSLL2 gene were labeled with Spectrum Green-dUTP (VYSIS, Downers Grove, IL, USA) and used as probes for FISH analysis. As shown in Figure 4 , speci®c signals were detected on human b Figure 1 Nucleotide and deduced amino acid sequences of human TSLL1 (a) and TSLL2 (b) genes. These sequences are available from GenBank under Accession Nos. AF363367 and AF363368, respectively. The two dierent polyadenylation sites are dotted in TSLL1 Oncogene TSLL1 and TSLL2, family genes of the tumor suppressor TSLC1 H Fukuhara et al chromosome 1q and 19q when BAC clones 431A20 and 343M13 were hybridized to normal human metaphase chromosome spreads, respectively. These results are consistent with the ®nding that the cDNA sequences of TSLL1 and TSLL2 are identical to portions of the genomic sequences of the BAC clone 134P22 on chromosome 1q21.2-22 and the cosmid clone F22162 on chromosome 19q13.2, respectively.
Expression of TSLL1 and TSLL2 in human tissues and cancer cell lines
Expression of the TSLL1 and TSLL2 was examined in various human tissues by Northern blotting analysis. As shown in Figure 5a , TSLL1 was expressed exclusively in human adult and fetal brain. Corresponding to the results of the cDNA clones, two distinct transcripts of about 3.8 and 2.6 kb were present in almost the same amount in adult brain. On the other hand, a single TSLL2 transcript of approximately 2.4 kb was observed in brain, kidney and prostate predominantly followed by heart, skeletal muscle, pancreas, ovary, small intestine and colon ( Figure 5b) .
Next, we examined the expression of the TSLL1 and TSLL2 genes in panels of 12 human glioma or four prostate cancer cell lines. Northern blotting analysis revealed that TSLL1 expression was lost in all but one glioma cell line, SW1783, suggesting that loss of TSLC1 expression might possibly be involved in the development or progression of human gliomas ( Figure  6a ). Expression of the TSLL2 was absent in seven glioma cells (SW1088, SW1783, CCF-STTG1, U87-MG, U118-MG, T98G, and KG-1-C) or markedly reduced in four additional cell lines (Figure 6b ). TSLL2 expression was also lost in a prostate cancer cell line, PPC-1, and reduced in the other three cell lines from prostate cancer examined when compared with that in normal prostate tissues. These results suggest that loss of TSLL2 expression might be important for the malignant phenotype of human glioma or prostate cancer cell lines.
Discussion
We have isolated two new genes, TSLL1 and TSLL2, based on the structural homology with the tumor suppressor gene, TSLC1, in the sequences corresponding to the cytoplasmic domain of the gene product. Both gene products displayed signi®cant similarity with TSLC1 in not only the cytoplasmic domain but also the overall protein structure, including three immunoglubulin C2-type domains and one transmembrane domain (Figure 2 ). Furthermore, gene structure in terms of exon ± intron composition was highly con- Figure 2 Amino acid sequence alignment among the cytoplasmic domains of human TSLC1, human TSLL1, human TSLL2, human glycophorin C (hGLPC) (GenBank Accession No. P04921), human contactin-associated protein 2 (hCaspr2) (NP_054860), and Drosophila melanogaster Neurexin IV (dNRX) (X86685) proteins. Gaps are introduced to realize the best alignments. Conserved residues among the molecules are indicated by black boxes. The 13 amino acids essential for binding to protein 4.1 in hGLPC are indicated by underbars (Marfatia et al., 1995) , while the three consensus amino acids (Y/F-F-I) at the COOH terminal for PDZ binding are indicated by a double underline Songyang et al., 1997) These results strongly suggest that these three genes belong to a distinct subfamily (TSLC1-gene family) in the immunoglobulin superfamily genes. When focused on the cytoplasmic domain, TSLL1 displayed high similarity with not only TSLC1 but also human glycophorin C, human contactin-associated protein 2 (Caspr2), and Drosophila Neurexin IV (NRX) (76, 49, 47 and 46% identical in the amino acid sequences, respectively), while TSLL2 showed relatively weak but signi®cant similarity to these four proteins (37, 36, 32 and 37% identical in the amino acid sequences, respectively) (Figure 2) . The extracellular domains of glycophorin C, Caspr2, or NRX, however, are not structurally related to TSLC1-gene family proteins. In glycophorin C, 13 amino acids juxtaposed to the plasma membrane are identi®ed as a minimal essential region for binding to protein 4.1 (Funayama et al., 1991 , Marfatia et al., 1995 . It is noteworthy that TSLC1, TSLL1, and TSLL2 showed signi®cant homology within this region (Figure 2 ). Moreover, a COOH-terminal portion of glycophorin C was shown to interact with a PDZ domain of p55, a homologous molecule of the Drosophila tumor suppressor protein, Dlg . The three consensus amino acids (Y/F-F-I) at the COOH end for PDZ binding are all conserved in TSLC1, TSLL1, and TSLL2 Songyang et al., 1997) . Drosophila NRX, a transmembrane protein localized in septate junctions of epithelial and glial cells, and its human ortholog, hCaspr2, are additional molecules that display signi®cant homology with the cytoplasmic domains of TSLC1-gene family proteins. Caspr2 is localized in myelinated axons and associated with K + channels (Poliak et al., 1999) , while the¯ies homozygous to the mutant NRX gene are embryonic lethal with paralysis caused by a breakdown of the glial septate junction, indicating the involvement of these molecules in the interaction between the adjacent cells (Baumgartner et al., 1996) . Taken together, these results indicate that TSLL1 and TSLL2 as well as TSLC1 might possibly play important roles in the formation of some kind of cell-to-cell or cell-tosubstrate junction.
The exon ± intron structures are strikingly conserved among the three genes except for exon 8 of the TSLC1 gene. This exon of 84 bp contains eleven ACC triplets preceded by two ACA triplets that encode 13 continuous threonine residues, suggesting that exon 8 appeared relatively recently in the evolution of the TSLC1 gene.
In spite of the structural similarity, the pattern of expression is quite dierent among these genes. Expression of TSLL1 is only detected in the brain, (A) + RNA. Lane 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas; 9, spleen; 10, thymus; 11, prostate; 12, testis; 13, ovary; 14, small intestine; 15, colon; 16, peripheral blood cell; 17, fetal brain; 18, fetal lung; 19, fetal liver; 20, fetal kidney while that of TSLL2 is restricted to the prostate, brain, kidney and some other organs, both presenting striking contrast to the ubiquitous expression of TSLC1. Although the physiological function of TSLL1 and TSLL2 remains to be clari®ed, it is suggestive that most of human glioma cell lines lost the expression of TSLL1 and/or TSLL2. Presence of mRNA in a subset of glioma cell lines suggests that TSLL1 and TSLL2 are essentially expressed in the glial cell lineage in human brain tissues but absent in tumor cells. It is noteworthy that at least six out of 12 glioma cell lines showed diminished expression of both TSLL1 and TSLL2 genes, suggesting that loss of both proteins might have synergistic eect in development or progression of cancer cells. A prostate cancer cell line PPC-1 also lacked TSLL2 expression. In addition to loss of expression in cancer cells, chromosomal alterations including the loci of TSLL1 (1q21.2-22) and TSLL2 (19q13.2) in the relevant tumors also imply their possible involvement in human tumors. These ®ndings include LOH on 1q in some gliomas (Nishizaki et al., 1998; Debiec-Rychter et al., 1995) and frequent LOH on 19 q in gliomas (Smith et al., 1999; Rosenberg et al., 1996) or ovarian cancers (Bicher et al., 1997) . Taken together, these ®ndings indicate that TSLL1 and TSLL2 could play some roles in the relevant tissues and tumors developed there in tissue-speci®c manner. In the case of the TSLC1 on 11q23, identi®cation of mutational inactivation or promoter methylation associated with LOH in primary tumors led to the conclusion that TSLC1 was a tumor suppressor gene (Kuramochi et al., 2001 ). Analysis of mutation or methylation in tumors as well as the functional study of the gene products of TSLL1 and TSLL2 would elucidate the physiological and pathological roles of these proteins.
Materials and methods
Isolation and sequencing of cDNA clones
Amino acid sequences homologous to the 46 residues of the whole cytoplasmic domain of TSLC1 were examined using the advanced BLAST program (http://www.ncbi.nlm.nih.gov/ BLAST/). A human adult brain-derived cDNA library, Lambda Trip1Ex, was purchased from Clontech (Palo Alto, CA, USA). Probes used for cDNA library screening were PCR-derived cDNA fragments of 1109 bp for TSLL1 (primers; 5'-ACAGCCAGCCCTGGACAT-3', 5'-CTAGAT-GAAATATTCCTTCTTGT-3') and 1103 bp for TSLL2 (primers; 5'-GGGCAGGACAGGAAGTACA-3', 5'-TCA-GATGAAGAATTCCTCTTTCC-3'), respectively. Rapid ampli®cation of the 5' end of TSLL2 cDNA was carried out using the Marathon-Ready cDNA Kit (Clontech, Palo Alto, CA, USA) with the adaptor primer (5'-CCATCCTAATAC-GACTCACTATAGGGC-3') and the gene speci®c primer (5'-CTTCTGTGTAGAGCTGGCAGAAATAG-3'). DNA sequences were determined by the BigDye terminator cycle sequencing ready kit (Perkin-Elmer, Branchburg, NJ, USA) on an ABI 377 DNA auto-sequencer (Applied Biosystems, Foster City, CA, USA).
Determination of the genomic structure
High-density ®lters of an RPCI-11 human BAC library were purchased from Research Genetics (Huntsville, AL, USA) and hybridized with the cDNA probes corresponding to the whole coding sequences of TSLL1 and TSLL2 according to the manufacturer's recommendation. BAC DNAs from clones 431A20 containing TSLL1 and clones 343M13 containing TSLL2 were used as templates to determine portions of the genomic sequences of TSLL1 and TSLL2, respectively. FISH was carried out as described previously (Pinkel et al., 1986) . DNA puri®ed from BAC clones was labeled with Spectrum Green-dUTP (VYSIS, Downers Grove, IL, USA) using a nick translation kit (Boehringer, Mannheim, Germany) as described previously (Shimura et al., 1999) and directly used as a probe for detection of the chromosomal loci of the TSLL1 and TSLL2 genes. Probes for the telomeric regions of human chromosome 1q and 19q were purchased from VYSIS (Downers Grove, IL, USA) and labeled with Spectrum Orange-dUTP similarly. After hybridization, cells and chromosomes were counterstained with 4', 6-diamidino-2-phenylindole (DAPI) in an antifade solution composed of 0.1% p-phenylenediamine and 90% glycerol (Wako Pure Chemicals, Tokyo, Japan). Digital images were captured using a¯uorescent microscope (Olympus, Tokyo, Japan) and analysed with CytoVision (Applied Imaging, Santa Clara, CA, USA). In all cases, a minimum of 20 metaphase nuclei was examined.
Cell lines
A human prostate cancer cell line, PPC-1, was kindly provided by Dr AR Brothman from the Medical School at the University of Utah. Human glioma cell lines, Hs683, SW1088, SW1783, DBTRG-05MG, CCF-STTG1, U87-MG, U118-MG, and U373-MG, and human prostate cancer cell lines, PC-3, LNCaP, and DU145, were obtained from American Type Culture Collection (Rockville, MD, USA). Human glioma cell lines, T98G, A-172, YKG-1, and KG-1-C, were from the Health Science Research Resources Bank (Osaka, Japan). These cell lines were cultured according to the supplier's recommendation.
Northern blotting analysis
Human multiple-tissue Northern blot membrane, adult brain or prostate poly(A) + RNA, and a cDNA probe for human beta-actin were obtained from Clontech (Palo Alto, CA, USA). Poly(A) + RNA from glioma or prostate cancer cell lines was extracted using the FastTrack 2.0 kit (Invitrogen, Carlsbad, CA, USA). Poly(A) + RNA of 1 ug was subjected to electrophoresis in a 1% agarose gel containing 2.1 M formamide and transferred onto a Hybond-N + nylon membrane (Amersham, Cleveland, OH, USA). Coding sequences of TSLL1 and TSLL2 cDNA were used as a probe. Hybridization was carried out at 428C for 18 h in 56SSC, 20 mM sodium phosphate, 16Denhardt's solution, 0.2% SDS, 100 ug/ml denatured salmon testis DNA, 10% dextran sulfate, and 50% formamide. Membranes were then washed with 26SSC/0.1% SDS at 428C for 15 min and with 0.16SSC/0.1% SDS at 508C for 15 min followed by exposure for 1 ± 4 days at 7708C with an intensifying screen.
